Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research led by the University of Oxford has revealed how the complex cultural and social environment in developing countries can complicate the use of new diagnostic technologies to fight the global superbug crisis.

Image courtesy of Shutterstock

The research, led by Dr Marco J Haenssgen at the CABDyN Complexity Centre and the Centre for Tropical Medicine and Global Health,  involved a new finger-prick blood test (C-reactive protein) to help nurses and doctors decide whether their patients need antibiotic treatment.

The superbug crisis has arisen because microbes are becoming increasingly resistant to antibiotics and other antimicrobials. The severity of the problem has been described in a recent World Bank report entitled 'Drug-Resistant Infections: A Threat to Our Economic Future', which warns that the current trends of antimicrobial use can entail 'a reversal of the public-health gains of the past century, and the economic growth, development, and poverty reduction these gains enabled.'

Find out more (University of Oxford website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.